Thibaut Mongon is Executive Vice President, Worldwide Chairman, Consumer Health at Johnson & Johnson. He serves on the corporation’s Executive Committee and chairs the Consumer Health Leadership Team. In his role, Thibaut leads the global development of J&J’s personal health portfolio that spans OTC/self care, skin health/beauty, oral care, baby care, women’s health and wound care, generating approximately $14 Billion in revenue. Leading operations in more than 140 countries with 19,000 associates, Thibaut is steward of a differentiated portfolio of iconic brands, including Tylenol®, Nicorette®, Zyrtec®, Neutrogena®, Aveeno®, Listerine®, OGX®, BAND-AID® and Johnson’s®.
Under his leadership, the Consumer Health team accelerated growth through portfolio optimization with a singular focus on personal health and a concentration on markets where Consumer Health could make the biggest impact. To help people live healthier lives every day, Thibaut mobilized an end-to-end approach to life-enhancing innovation that delivers solutions rooted in science and endorsed by professionals. Adept at navigating consumer and market shifts, Thibaut has advanced a digital-first ambition to grow ecommerce and digital capabilities to create frictionless interactions with consumers and health care professionals, drive innovation and improve supply chain’s agility. He is also invested in delivering on an ambitious sustainability agenda.
Thibaut is a seasoned global leader with more than 20 years at Johnson & Johnson. He inspires a one team mindset, leading with purpose and always staying grounded in Our Credo. He draws on his knowledge working across five continents and all three sectors of Johnson & Johnson to empower an agile, end-to-end organization to develop solutions that improve health outcomes for 1.2 billion consumers globally.
Before being elevated to his current role, Thibaut served as Company Group Chairman, Johnson & Johnson Consumer Health Asia-Pacific. From 2014 until early 2019, Thibaut led the transformation of this region into an engine of accelerated revenue growth by creating a vibrant pipeline of consumer-centric innovation. He also drove significant value through both external partnerships and strategic acquisitions, helping to future-proof the portfolio.
Thibaut joined Johnson & Johnson in 2000 as Director of Marketing for the Vision Care group (Medical Devices) in France and subsequently held general management positions as Country Manager France, Belgium and North Africa, Managing Director Latin America, and President Asia-Pacific. Thibaut transitioned to the Pharmaceutical Group of Johnson & Johnson in 2012 as the Global Commercial Strategy Leader for the Neuroscience therapeutic area, based in the U.S.
Prior to joining Johnson & Johnson, Thibaut worked for Bormioli in Italy and Danone in France.
Thibaut serves on the board of the Consumer Goods Forum.
Thibaut holds degrees in Business Administration from the KEDGE Bordeaux Business School and a Master of Business Administration from INSEAD.
What is Thibaut Mongon's net worth?
The estimated net worth of Thibaut Mongon is at least $6.30 million as of November 4th, 2022. Mr. Mongon owns 40,133 shares of Johnson & Johnson stock worth more than $6,295,664 as of July 13th. This net worth estimate does not reflect any other assets that Mr. Mongon may own. Learn More about Thibaut Mongon's net worth.
How do I contact Thibaut Mongon?
Has Thibaut Mongon been buying or selling shares of Johnson & Johnson?
Thibaut Mongon has not been actively trading shares of Johnson & Johnson during the last ninety days. Most recently, Thibaut Mongon sold 35,246 shares of the business's stock in a transaction on Friday, November 4th. The shares were sold at an average price of $171.18, for a transaction totalling $6,033,410.28. Following the completion of the sale, the vice president now directly owns 40,133 shares of the company's stock, valued at $6,869,966.94. Learn More on Thibaut Mongon's trading history.
Who are Johnson & Johnson's active insiders?
Johnson & Johnson's insider roster includes Dominic Caruso (VP), Robert Decker (CAO), Joaquin Duato (CEO & Chairman), Peter Fasolo (VP), Alex Gorsky (CEO), William Hait (Insider), Ronald Kapusta (CAO), Ashley McEvoy (EVP), Thibaut Mongon (VP), William Perez (Director), Timothy Schmid (EVP, Worldwide Chairman, MedTech), Michael Sneed (COO), Paulus Stoffels (VP), James Swanson (EVP), Jennifer Taubert (EVP), Mark Weinberger (Director), Kathryn Wengel (EVP), Joseph Wolk (CFO), and Joseph Wolk (Exec. VP & CFO ). Learn More on Johnson & Johnson's active insiders.
Are insiders buying or selling shares of Johnson & Johnson?
During the last year, Johnson & Johnson insiders bought shares 1 times. They purchased a total of 1,000 shares worth more than $147,220.00. During the last year, insiders at the sold shares 3 times. They sold a total of 13,037 shares worth more than $2,154,035.67. The most recent insider tranaction occured on February, 25th when VP Robert J Decker sold 6,999 shares worth more than $1,160,994.12. Insiders at Johnson & Johnson own 0.2% of the company.
Learn More about insider trades at Johnson & Johnson. Information on this page was last updated on 2/25/2025.
